BCL2 and B-cell chronic lymphocytic leukemia: Preliminary results presented at the 2024 ASH meeting show a high response rate with another novel BCL-2 inhibitor, lisaftoclax combined with acalabrutinib in relapsed/refractory and treatment-naïve patients with CLL (40).